Clinical trials: Acute Lymphoblastic Leukemia Recurrent
- Condition Acute Lymphoblastic Leukemia Recurrent
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Malignancies, Acute Lymphoblastic Leukemia (ALL)
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary…
- Conditions
- Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma
- Trial name
- NCT03236857
- Testing
- chemotherapy, venetoclax
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 143 people
- Sponsor
- AbbVie
Leukemia
Aminopterin in Treating Patients With Refractory Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminopterin in treating patients who have refractory…
- Trial name
- NCT00003305
- Testing
- aminopterin, leucovorin calcium
- Where
- 14 sites in United States
- Volunteers
- 75 people
- Sponsor
- Genzyme, a Sanofi Company
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics
Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL
Primary Objective: To estimate the incidence of treatment-emergent and treatment-related adverse events during treatment with blinatumomab in pediatric and adolescent subjects with B-precursor ALL in second or later bone marrow…
- Trial name
- RIALTO (NCT02187354)
- Testing
- Blinatumomab, Extension of LTFU as per ProtocolAmendment7 7Jun18
- Where
- 19 sites in United States, Austria and 5 more
- Sponsor
- Amgen
Fever, Sweats, and Hot Flashes, Infection
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
RATIONALE: Recombinant human mannose-binding lectin (MBL) may be effective in preventing infection in young patients with fever and neutropenia receiving chemotherapy for blood disease or cancer.
- Conditions
- Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma
- Trial name
- NCT00886496
- Testing
- recombinant human mannose-binding lectin
- Where
- 3 sites in United States
- Sponsor
- Enzon Pharmaceuticals, Inc.
Leukemia, Lymphoma
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. BL22 immunotoxin may be effective in treating relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
- Trial name
- NCT00077493
- Testing
- BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- MedImmune LLC
Acute Lymphoblastic Leukemia, in Relapse
GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia
Asparaginase is a cornerstone in the treatment of ALL, but its utility is limited by toxicities including hypersensitivity. Clinical allergy is associated with inactivation of asparaginase by antibodies (A-Abs), which can also…
- Trial name
- GRASPIVOTALL (NCT01518517)
- Testing
- GRASPA, L-asparaginase
- Where
- 28 sites in Belgium, France
- Volunteers
- 85 people
- Sponsor
- ERYtech Pharma
Non Hodgkin Lymphoma, Richter Transformation
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing…
- Conditions
- Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia
- Trial name
- NCT04771572
- Testing
- LP-118
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Newave Pharmaceutical Inc
Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood, Refractory B-cell Acute Lymphoblastic Leukemia, Childhood
A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma
This is a single arm, open-label, uni-center, phase I study . In this study, Children withCD19+/CD22+ R/R B-cell acute lymphoblastic leukemia or lymphoma will be treated with CAR-T19/CAR-T22 Immunotherapy to determine the safety…
- Conditions
- Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood, Refractory B-cell Acute Lymphoblastic Leukemia, Childhood, Relapsed/Refractory B-cell Lymphoma, Childhood
- Trial name
- NCT04204161
- Testing
- CAR-T19/CAR-T22
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen BinDeBio Ltd.
Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia, B-cell Precursor Acute Lymphoblastic Leukaemia
Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.
The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics and safety of different doses of intravenous and oral Forodesine in children with relapsed or refractory T-cell or B-cell precursor Acute…
- Conditions
- Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia, B-cell Precursor Acute Lymphoblastic Leukaemia, T-cell Non-Hodgkin's Lymphoma
- Trial name
- BCX1777-108 (NCT00742495)
- Testing
- Forodesine
- Where
- 6 sites in Austria, Czechia and 4 more
- Volunteers
- 2 people
- Sponsor
- Mundipharma Research Limited
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia…
- Trial name
- ZUMA-4 (NCT02625480)
- Testing
- Brexucabtagene Autoleucel (KTE-X19), Fludarabine, Cyclophosphamide
- Where
- 30 sites in United States, Belgium and 9 more
- Volunteers
- 95 people
- Sponsor
- Kite, A Gilead Company
Acute Lymphoblastic Leukemia
Phase III B in Acute Lymphoblastic Leukemia
This is a single arm, open-label, multi-center, phase III B study to determine the safety and efficacy of CTL019 in pediatric/young adult patients with r/r B-cell Acute Lymphoblastic Leukemia (ALL).
- Trial name
- NCT03123939
- Testing
- CTL019
- Where
- 11 sites in Austria, Belgium and 7 more
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid tumors.
- Conditions
- Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia
- Trial name
- NCT03934372
- Testing
- Ponatinib
- Where
- 23 sites in Belgium, France and 5 more
- Volunteers
- 70 people
- Sponsor
- Incyte Biosciences International Sàrl
Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD7 CAR-T cells in patients with relapsed and/or refractory, high risk hematologic malignancies.
- Trial name
- NCT05212584
- Testing
- CD7CAR T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- iCell Gene Therapeutics
Leukemia, Lymphoma
Study of @neWorld: A Virtual Community for Children With Cancer
RATIONALE: Using an Internet Web site that enables children with cancer to interact online with classmates, participate in classroom activities, get easy-to-read medical information, and chat with family members, medical staff…
- Conditions
- Leukemia, Lymphoma, Psychosocial Effects of Cancer and Its Treatment, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00070421
- Testing
- complementary or alternative medicine procedure, management of therapy complications, psychosocial assessment and care
- Where
- United States
- Sponsor
- Leap of Faith Technologies
Acute Lymphocytic Leukemia Refractory, Lymphoma, Lymphoblastic
A Study of CTD402 in T-ALL/LBL Patients
The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients.
- Trial name
- TENACITY-01 (NCT07070219)
- Testing
- CTD402 CAR T Cell Injection
- Where
- 9 sites in United States, Australia
- Volunteers
- 118 people
- Sponsor
- Imviva Bio
Lymphoma, Non-Hodgkin, Hodgkin Disease
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma…
- Trial name
- RELATIVITY-069 (NCT05255601)
- Testing
- Relatlimab, Nivolumab
- Where
- 51 sites in United States, Australia and 5 more
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma
The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma
This is a single-arm, open-label, multicenter, phase III clinical study that aims to evaluate the efficacy and safety of Nelarabine injection in the treatment of refractory or recurrent T-lymphoblastic leukemia (T-ALL) and…
- Trial name
- NCT06434467
- Testing
- Nelarabine injection
- Where
- 30 sites in China
- Volunteers
- 83 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood, Refractory B-cell Acute Lymphoblastic Leukemia, Childhood
A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects
This is a single arm, open-label, uni-center, phase I/II study to determine the safety and efficacy of an experimental therapy called BinD19 cells in childhood patients with B-cell acute lymphoblastic leukemia or lymphoma, who…
- Conditions
- Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood, Refractory B-cell Acute Lymphoblastic Leukemia, Childhood, Relapsed/Refractory B-cell Lymphoma, Childhood
- Trial name
- NCT03265106
- Testing
- BinD19
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen BinDeBio Ltd.
Leukemia, Myelodysplastic Syndromes
Chemotherapy in Treating Patients Who Have Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating patients who have hematologic…
- Trial name
- NCT00004047
- Testing
- exatecan mesylate
- Where
- United States
- Sponsor
- Daiichi Sankyo